Ascendis Pharma A/S
ASND
$161.52
$7.094.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.58M | -41.01M | -109.06M | -117.73M | -142.25M |
| Total Depreciation and Amortization | 4.78M | 4.27M | 4.81M | 4.72M | 4.86M |
| Total Amortization of Deferred Charges | -- | 497.80K | -- | -- | -- |
| Total Other Non-Cash Items | 26.88M | 65.20M | -47.33M | 63.86M | 91.07M |
| Change in Net Operating Assets | 52.86M | -121.89M | 89.87M | -16.84M | -63.96M |
| Cash from Operations | -15.06M | -92.93M | -61.71M | -65.99M | -110.28M |
| Capital Expenditure | -739.80K | -446.60K | -513.40K | -368.10K | -216.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 1.02M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 37.30K | -39.60K | 0.00 | 7.98M |
| Cash from Investing | -739.80K | -409.30K | -553.00K | 654.40K | 7.77M |
| Total Debt Issued | -- | 0.00 | 134.16M | -- | -- |
| Total Debt Repaid | -3.07M | -2.95M | -2.81M | -2.82M | -2.79M |
| Issuance of Common Stock | 13.83M | 22.33M | 296.53M | 365.00K | 21.21M |
| Repurchase of Common Stock | -28.79M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -19.29M | -- | -- | -- |
| Cash from Financing | -18.97M | 92.70K | 470.39M | -2.64M | 20.00M |
| Foreign Exchange rate Adjustments | -9.03M | 22.92M | -4.86M | 1.74M | 4.43M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.80M | -70.32M | 403.27M | -66.24M | -78.08M |